Biocentury is celebrating 25 years in business having hosted last week their 24th Future Leaders conference which is the longest running independent investment conference serving the biopharma industry; helping showcase biotech companies independently vetted by BioCentury, developing best-in-class products and discovery platforms in important disease areas. The 2017 Class follows this theme, with a rich mix of product and platform companies with ample milestone opportunities in front of them.
This year, the conference featured 50+ companies from a variety innovative science and platform assets, plus later stage compounds with near-term commercial milestones. Also included are an international track of companies with key value drivers, companies working on new targets in regenerative medicine, neurological conditions and cancer including CAR-T. BioCentury also continues to shine a light on emerging private companies ready to hut the Street’s radar trough our track of Next Wave companies.
This conference year’s Future Leaders class has raised more than $3.6 billion in capital. Of this total, nearly $1.6 billion has come since the beginning of 2015, with nearly $750 million coming in the past 5 quarters. For more information. www.biocentury.com